Compare Natera Inc. Common Stock (NTRA) vs ON Holding AG (ONON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs ON Holding AG — how do they compare? Natera Inc. Common Stock trades at $395.89 (market cap $57.03B), while ON Holding AG trades at $35.36 (market cap $11.86B). The key difference: Natera Inc. Common Stock is far larger — about 4.8× ON Holding AG's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, ON Holding AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and ON Holding AG for 24 Days on average.
| NTRA | ONON | |
|---|---|---|
Market Cap | $57.03B | $11.86B |
Volume | 1,131,157 | 10,043,743 |
Sector | Health | Consumer Cyclical |
52-Week High | $425.64 | $50.63 |
52-Week Low | $179.42 | $26.76 |
Typical Hold Time | 0 Days | 24 Days |
Enterprise Value | $56.18B | $11.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
ONON trades at $35.14, down 0.99% on the day, with a bullish technical signal from moving averages but bearish oscillators. The company reported strong quarterly earnings beats, with Q2 2026 EPS of $0.44 exceeding the $0.42 estimate. Revenue for 2025 was $3.01 billion, with a net income margin of 12.3% and robust cash flow from operations of $359.5 million. Recent news highlights a $1 billion share buyback authorization through 2029 and ambitious long-term growth targets.
The outlook is positive, supported by earnings momentum, a shareholder-friendly buyback, and analyst consensus favoring buys. Key risks include high valuation multiples, competitive pressures in footwear, and reliance on premium brand execution. Upside to the $42.26 consensus price target offers potential, but investors should weigh growth sustainability against current premiums.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →
